|
Gene: RPLP1 |
Gene summary for RPLP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPLP1 | Gene ID | 6176 |
Gene name | ribosomal protein lateral stalk subunit P1 | |
Gene Alias | LP1 | |
Cytomap | 15q23 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | A0A024R608 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6176 | RPLP1 | CA_HPV_2 | Human | Cervix | CC | 7.41e-13 | -1.77e-01 | 0.0391 |
6176 | RPLP1 | CA_HPV_3 | Human | Cervix | CC | 5.39e-04 | 7.76e-02 | 0.0414 |
6176 | RPLP1 | CCI_1 | Human | Cervix | CC | 2.51e-72 | -2.11e+00 | 0.528 |
6176 | RPLP1 | CCI_2 | Human | Cervix | CC | 6.31e-34 | -1.30e+00 | 0.5249 |
6176 | RPLP1 | CCI_3 | Human | Cervix | CC | 4.75e-105 | -2.24e+00 | 0.516 |
6176 | RPLP1 | CCII_1 | Human | Cervix | CC | 7.88e-107 | -2.37e+00 | 0.3249 |
6176 | RPLP1 | Tumor | Human | Cervix | CC | 3.13e-17 | -1.27e-01 | 0.1241 |
6176 | RPLP1 | sample1 | Human | Cervix | CC | 1.32e-10 | -1.83e-01 | 0.0959 |
6176 | RPLP1 | sample3 | Human | Cervix | CC | 3.05e-35 | -2.05e-01 | 0.1387 |
6176 | RPLP1 | H2 | Human | Cervix | HSIL_HPV | 2.18e-64 | -4.01e-01 | 0.0632 |
6176 | RPLP1 | T1 | Human | Cervix | CC | 3.50e-36 | -2.73e-01 | 0.0918 |
6176 | RPLP1 | T3 | Human | Cervix | CC | 1.76e-39 | -2.05e-01 | 0.1389 |
6176 | RPLP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.34e-103 | 2.47e+00 | 0.0155 |
6176 | RPLP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.58e-61 | 3.27e+00 | -0.1808 |
6176 | RPLP1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.59e-38 | 3.52e+00 | 0.0216 |
6176 | RPLP1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.98e-61 | 3.15e+00 | -0.0811 |
6176 | RPLP1 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.59e-47 | 1.71e+00 | -0.1088 |
6176 | RPLP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.75e-95 | 3.39e+00 | -0.1954 |
6176 | RPLP1 | HTA11_411_2000001011 | Human | Colorectum | SER | 8.01e-26 | 3.42e+00 | -0.2602 |
6176 | RPLP1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.76e-19 | 3.28e+00 | -0.2196 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0033674110 | Skin | SCCIS | positive regulation of kinase activity | 44/919 | 467/18723 | 2.75e-05 | 7.56e-04 | 44 |
GO:0045860110 | Skin | SCCIS | positive regulation of protein kinase activity | 35/919 | 386/18723 | 3.66e-04 | 6.19e-03 | 35 |
GO:0006414110 | Skin | SCCIS | translational elongation | 9/919 | 55/18723 | 1.32e-03 | 1.53e-02 | 9 |
GO:000218129 | Skin | cSCC | cytoplasmic translation | 127/4864 | 148/18723 | 4.83e-53 | 7.57e-50 | 127 |
GO:000641423 | Skin | cSCC | translational elongation | 30/4864 | 55/18723 | 6.13e-06 | 8.70e-05 | 30 |
GO:003367425 | Skin | cSCC | positive regulation of kinase activity | 148/4864 | 467/18723 | 3.00e-03 | 1.66e-02 | 148 |
GO:004586025 | Skin | cSCC | positive regulation of protein kinase activity | 123/4864 | 386/18723 | 5.23e-03 | 2.64e-02 | 123 |
GO:00021816 | Stomach | GC | cytoplasmic translation | 62/1159 | 148/18723 | 5.06e-36 | 2.75e-32 | 62 |
GO:000218111 | Stomach | CAG with IM | cytoplasmic translation | 61/1050 | 148/18723 | 1.99e-37 | 1.06e-33 | 61 |
GO:000218121 | Stomach | CSG | cytoplasmic translation | 62/1034 | 148/18723 | 6.36e-39 | 3.36e-35 | 62 |
GO:000218131 | Stomach | CAG | cytoplasmic translation | 60/552 | 148/18723 | 9.60e-53 | 4.29e-49 | 60 |
GO:00064144 | Stomach | CAG | translational elongation | 7/552 | 55/18723 | 1.11e-03 | 1.51e-02 | 7 |
GO:00336746 | Stomach | CAG | positive regulation of kinase activity | 24/552 | 467/18723 | 6.24e-03 | 4.93e-02 | 24 |
GO:000218141 | Stomach | WIM | cytoplasmic translation | 50/426 | 148/18723 | 4.78e-45 | 1.90e-41 | 50 |
GO:000218151 | Stomach | SIM | cytoplasmic translation | 61/708 | 148/18723 | 1.54e-47 | 7.28e-44 | 61 |
GO:000641411 | Stomach | SIM | translational elongation | 7/708 | 55/18723 | 4.50e-03 | 3.94e-02 | 7 |
GO:000218130 | Thyroid | HT | cytoplasmic translation | 92/1272 | 148/18723 | 1.18e-69 | 6.57e-66 | 92 |
GO:003367426 | Thyroid | HT | positive regulation of kinase activity | 51/1272 | 467/18723 | 5.42e-04 | 6.46e-03 | 51 |
GO:000641424 | Thyroid | HT | translational elongation | 11/1272 | 55/18723 | 1.02e-03 | 1.04e-02 | 11 |
GO:004586020 | Thyroid | HT | positive regulation of protein kinase activity | 41/1272 | 386/18723 | 3.01e-03 | 2.43e-02 | 41 |
Page: 1 2 3 4 5 6 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPLP1 | deletion | Frame_Shift_Del | c.339delT | p.Phe113LeufsTer7 | p.F113Lfs*7 | P05386 | protein_coding | TCGA-CK-5912-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
RPLP1 | SNV | Missense_Mutation | novel | c.64N>T | p.Thr22Ser | p.T22S | P05386 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
RPLP1 | SNV | Missense_Mutation | novel | c.200G>T | p.Gly67Val | p.G67V | P05386 | protein_coding | deleterious(0.02) | possibly_damaging(0.903) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
RPLP1 | SNV | Missense_Mutation | rs766033183 | c.149N>T | p.Ala50Val | p.A50V | P05386 | protein_coding | tolerated(0.06) | possibly_damaging(0.764) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
RPLP1 | SNV | Missense_Mutation | c.299N>G | p.Glu100Gly | p.E100G | P05386 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |